Literature DB >> 24819215

"In vitro" 3D models of tumor-immune system interaction.

Christian Hirt1, Adam Papadimitropoulos2, Valentina Mele1, Manuele G Muraro1, Chantal Mengus1, Giandomenica Iezzi3, Luigi Terracciano4, Ivan Martin5, Giulio C Spagnoli6.   

Abstract

Interaction between cancer cells and immune system critically affects development, progression and treatment of human malignancies. Experimental animal models and conventional "in vitro" studies have provided a wealth of information on this interaction, currently used to develop immune-mediated therapies. Studies utilizing three-dimensional culture technologies have emphasized that tumor architecture dramatically influences cancer cell-immune system interaction by steering cytokine production and regulating differentiation patterns of myeloid cells, and decreasing the sensitivity of tumor cells to lymphocyte effector functions. Hypoxia and increased production of lactic acid by tumor cells cultured in 3D architectures appear to be mechanistically involved. 3D culture systems could be further developed to (i) include additional cell partners potentially influencing cancer cell-immune system interaction, (ii) enable improved control of hypoxia, and (iii) allow the use of freshly derived clinical cancer specimens. Such advanced models will represent new tools for cancer immunobiology studies and for pre-clinical assessment of innovative treatments.
Copyright © 2014 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Cancer; Hypoxia; Immune system; Perfusion bioreactors; Three-dimensional cultures

Mesh:

Substances:

Year:  2014        PMID: 24819215     DOI: 10.1016/j.addr.2014.05.003

Source DB:  PubMed          Journal:  Adv Drug Deliv Rev        ISSN: 0169-409X            Impact factor:   15.470


  35 in total

Review 1.  Manufacturing Cell Therapies Using Engineered Biomaterials.

Authors:  Amr A Abdeen; Krishanu Saha
Journal:  Trends Biotechnol       Date:  2017-07-12       Impact factor: 19.536

Review 2.  3D bioprinting for reconstituting the cancer microenvironment.

Authors:  Pallab Datta; Madhuri Dey; Zaman Ataie; Derya Unutmaz; Ibrahim T Ozbolat
Journal:  NPJ Precis Oncol       Date:  2020-07-27

3.  Ex-vivo assessment of drug response on breast cancer primary tissue with preserved microenvironments.

Authors:  Manuele G Muraro; Simone Muenst; Valentina Mele; Luca Quagliata; Giandomenica Iezzi; Alexandar Tzankov; Walter P Weber; Giulio C Spagnoli; Savas D Soysal
Journal:  Oncoimmunology       Date:  2017-05-30       Impact factor: 8.110

Review 4.  Biomaterials and emerging anticancer therapeutics: engineering the microenvironment.

Authors:  Luo Gu; David J Mooney
Journal:  Nat Rev Cancer       Date:  2016-01       Impact factor: 60.716

5.  Microfluidics: A new tool for modeling cancer-immune interactions.

Authors:  Alexandra Boussommier-Calleja; Ran Li; Michelle B Chen; Siew Cheng Wong; Roger D Kamm
Journal:  Trends Cancer       Date:  2016-01-01

Review 6.  Molecular and Functional Diagnostic Tools in Precision Oncology for Urological Malignancies.

Authors:  Vasanthakumar Sekar; Debapriya Ghosh Mehrotra; Biswanath Majumder
Journal:  Indian J Surg Oncol       Date:  2016-12-15

Review 7.  Engineering opportunities in cancer immunotherapy.

Authors:  Laura Jeanbart; Melody A Swartz
Journal:  Proc Natl Acad Sci U S A       Date:  2015-11-24       Impact factor: 11.205

Review 8.  Precision medicine for cancer with next-generation functional diagnostics.

Authors:  Adam A Friedman; Anthony Letai; David E Fisher; Keith T Flaherty
Journal:  Nat Rev Cancer       Date:  2015-11-05       Impact factor: 60.716

9.  Into the depths: Techniques for in vitro three-dimensional microtissue visualization.

Authors:  Pranita K Kabadi; Marguerite M Vantangoli; April L Rodd; Elizabeth Leary; Samantha J Madnick; Jeffrey R Morgan; Agnes Kane; Kim Boekelheide
Journal:  Biotechniques       Date:  2015-11-01       Impact factor: 1.993

10.  Ex Vivo Profiling of PD-1 Blockade Using Organotypic Tumor Spheroids.

Authors:  Russell W Jenkins; Amir R Aref; Patrick H Lizotte; Elena Ivanova; Susanna Stinson; Chensheng W Zhou; Michaela Bowden; Jiehui Deng; Hongye Liu; Diana Miao; Meng Xiao He; William Walker; Gao Zhang; Tian Tian; Chaoran Cheng; Zhi Wei; Sangeetha Palakurthi; Mark Bittinger; Hans Vitzthum; Jong Wook Kim; Ashley Merlino; Max Quinn; Chandrasekar Venkataramani; Joshua A Kaplan; Andrew Portell; Prafulla C Gokhale; Bart Phillips; Alicia Smart; Asaf Rotem; Robert E Jones; Lauren Keogh; Maria Anguiano; Lance Stapleton; Zhiheng Jia; Michal Barzily-Rokni; Israel Cañadas; Tran C Thai; Marc R Hammond; Raven Vlahos; Eric S Wang; Hua Zhang; Shuai Li; Glenn J Hanna; Wei Huang; Mai P Hoang; Adriano Piris; Jean-Pierre Eliane; Anat O Stemmer-Rachamimov; Lisa Cameron; Mei-Ju Su; Parin Shah; Benjamin Izar; Manisha Thakuria; Nicole R LeBoeuf; Guilherme Rabinowits; Viswanath Gunda; Sareh Parangi; James M Cleary; Brian C Miller; Shunsuke Kitajima; Rohit Thummalapalli; Benchun Miao; Thanh U Barbie; Vivek Sivathanu; Joshua Wong; William G Richards; Raphael Bueno; Charles H Yoon; Juan Miret; Meenhard Herlyn; Levi A Garraway; Eliezer M Van Allen; Gordon J Freeman; Paul T Kirschmeier; Jochen H Lorch; Patrick A Ott; F Stephen Hodi; Keith T Flaherty; Roger D Kamm; Genevieve M Boland; Kwok-Kin Wong; David Dornan; Cloud Peter Paweletz; David A Barbie
Journal:  Cancer Discov       Date:  2017-11-03       Impact factor: 39.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.